Rinvoq (upadacitinib) causes acne as a direct consequence of how it works in the body. By blocking a specific immune signaling pathway called JAK1, the drug alters inflammatory activity in the skin in ways that trigger breakouts, particularly on the face. In clinical trials of atopic dermatitis patients, acne appeared in roughly 13 to 20% of people within the first 16 weeks of treatment, compared to about 6% on placebo.
How JAK1 Inhibition Triggers Breakouts
Rinvoq works by selectively blocking JAK1, an enzyme involved in transmitting signals from inflammatory molecules called cytokines. In conditions like atopic dermatitis, rheumatoid arthritis, and ulcerative colitis, this is exactly what you want: less inflammation. But JAK1 signaling also plays a role in regulating immune responses in the skin, and suppressing it appears to shift the skin’s inflammatory balance in a way that promotes acneiform lesions.
Importantly, these breakouts don’t behave quite like typical acne. In regular acne, oil glands overproduce sebum, pores get clogged, and bacteria multiply, creating a mix of blackheads, whiteheads, and inflamed bumps. With Rinvoq-associated breakouts, the inflammatory lesions (red papules and pustules) come first and dominate. There’s no clear hormonal driver, and oil glands don’t appear to be the primary target. Researchers have proposed calling this “JAK-acne” to distinguish it from conventional acne, since the underlying mechanism is fundamentally different even though the lesions look similar on the surface.
What It Looks Like and Where It Appears
In about 68% of reported cases, the breakouts are mild: small inflammatory papules and pustules concentrated on the face. The trunk (chest and back) is involved in roughly 32% of patients. Blackheads and whiteheads, which are hallmarks of traditional acne, are less prominent. Scarring has not been commonly reported, which aligns with the idea that the oil glands themselves aren’t being heavily affected.
If you’re used to the deep, cystic breakouts associated with hormonal acne, Rinvoq-related acne generally looks different. It tends to present as scattered red bumps and small pus-filled spots rather than large, painful nodules under the skin.
The Acne Is Dose-Dependent
Higher doses of Rinvoq produce more acne, which reinforces that the drug itself is the cause. In a Japanese phase 3 trial of atopic dermatitis patients, acne rates during the first 16 weeks broke down clearly by dose: 13.2% at 15 mg, 19.8% at 30 mg, and 5.6% on placebo. Over longer treatment periods, the gap widened further, with 17.3% of patients on 15 mg and 32.4% on 30 mg experiencing acne. These patterns were consistent across multiple large trials, confirming a reliable dose-response relationship.
When Breakouts Start and How Long They Last
Acne from Rinvoq typically shows up within the first couple months of treatment. In a case series tracking the onset timeline, the average was about 7 weeks after starting therapy, with a range of 3 to 16 weeks. So if you’ve been on Rinvoq for several months without any skin changes, you’re less likely to develop this side effect, though it’s not impossible.
The good news is that most cases are mild to moderate and manageable. Some patients see spontaneous resolution without doing anything at all. Others experience persistent breakouts that continue for as long as they remain on the medication. In the case series, one patient still had forehead acne at last follow-up, while another cleared up entirely on their own. The trajectory varies, but the breakouts rarely become severe enough to require stopping the drug.
How Rinvoq-Related Acne Is Managed
A significant portion of patients don’t need any treatment for the breakouts. In a post hoc analysis of three large phase 3 trials, about 40 to 47% of patients who developed acne required no intervention at all. For those who did need something, the approach mirrors standard acne care: topical antibiotics, benzoyl peroxide, and topical retinoids, used alone or in combination.
In some cases, doctors reduce the Rinvoq dose rather than adding acne treatments. Since the side effect is dose-dependent, stepping down from 30 mg to 15 mg can reduce breakouts while still controlling the underlying condition. This is a balancing act between managing your primary disease and keeping skin side effects tolerable. Most patients find a combination of topical treatments and, if needed, dose adjustment that keeps both under control.
Who Is More Likely to Get It
Acne from Rinvoq is most commonly reported in atopic dermatitis patients, where trial data is most robust. This may partly reflect the demographics of that population, which skews younger than rheumatoid arthritis or ulcerative colitis cohorts. Younger age is a known risk factor for acne in general, so it’s difficult to separate the drug’s effect from baseline susceptibility. The clearest predictor from clinical data is dose: if you’re on 30 mg, your risk is roughly double compared to 15 mg. Beyond that, there’s no well-established profile that reliably predicts who will or won’t break out.